Integrant, a Sydney-based technology company developing integrated solutions across artificial intelligence, medical technology, and biologics, has announced the successful closure of its Series A capital raise, originally opened in April 2025. The company is now actively exploring a pre-IPO placement ahead of its targeted Nasdaq listing under the proposed ticker INGT, expected in approximately seven months. Financial terms of the Series A were not disclosed.
The round attracted strong investor interest, and since initiating the raise, Integrant has achieved a series of technical milestones, including meaningful progress in the development of its AI platform. Following those advancements, management determined that the original allocation framework established at the outset of the Series A was no longer aligned with current priorities, prompting the decision to explore a pre-IPO placement rather than proceed under the original funding structure.
The prospective pre-IPO round is intended to provide an opportunity for investors who were unable to participate in the Series A to engage with the company ahead of a potential public listing. Proceeds are expected to support final-stage development, operational scaling, and market readiness initiatives as Integrant continues preparations for its Nasdaq debut.
